An observational study in Sarcopenia in Elderly and Falls, sponsored by Medway NHS Foundation Trust. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Medway NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Sarcopenia with a site in United Kingdom — 11 open to participants now, 14 under way, none of them phase 3. Sarcopenia · United Kingdom.
Among the 72 studies in Sarcopenia with a site in United Kingdom, this one is the 13th largest by planned enrollment of the 22 observational ones that give a count, is one of 2 that started in 2025, is one of 22 observational ones, reaches primary completion later than 9 of the 13 other live ones, and was the 69th registered.
1,333 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →11 of the 72 studies in Sarcopenia with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Nottingham · Sites in United Kingdom
Ages 65+ · Men only · Healthy volunteers
Barts & The London NHS Trust · Sites in United Kingdom
Ages 16+
University of Glasgow · Sites in United Kingdom
Ages 65–90 · Healthy volunteers
University of Bath · Sites in United Kingdom
Ages 65–85 · Healthy volunteers
University of Leicester · Sites in United Kingdom
Ages 18+ · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 120 across 455 observational studies indexed under Sarcopenia.
Median enrollment 33 across the 50 interventional studies, 132 across the 22 observational. Of the 41 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 72 have an industry lead sponsor. The 10 most frequent:
Medway NHS Foundation Trust is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Medway NHS Foundation Trust has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
2 of the studies in Sarcopenia with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07127692Medway NHS Foundation TrustPrevalence of Sarcopenia-Promoting Medicines in Patients With Sarcopenia and Falls | 2027-02 |
| NCT07916935The University of NorthamptonEccentric Exercise in Community-dwelling Older Adults | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 72 studies in Sarcopenia with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcopenia, characterised by the loss of muscle mass and function, is a common condition among the elderly and is often associated with increased risk of falls. Certain medications, such as glucocorticoids, statins, and some antipsychotics, may exacerbate sarcopenia, leading to a higher incidence of falls. This study aims to explore the prevalence of such medicines in patients diagnosed with sarcopenia who have experienced falls. Understanding the impact of these medications on sarcopenia and fall risk can inform clinical guidelines and improve patient outcomes.
Sarcopenia, the age-related loss of muscle mass and strength, is a recognised contributor to frailty, disability, and increased fall risk in older adults. While physical inactivity and comorbidities are known risk factors, increasing evidence suggests that certain medications - including corticosteroids, sedatives and statins - may also contribute to muscle decline. These medicines are frequently prescribed to older adults, but the extent of their use in patients with sarcopenia and falls remains poorly defined.
Falls clinics manage high-risk patients, yet there is currently limited research examining the prevalence of sarcopenia-promoting medications in this specific setting. This study addresses an important knowledge gap by estimating the prevalence of these medicines in older adults attending a secondary care falls clinic, and by exploring associations with sarcopenia and fall history.
The findings will support a better understanding of medication-related risk factors for sarcopenia and may help guide future deprescribing and medication review strategies. This aligns with current priorities in geriatric medicine to reduce inappropriate polypharmacy and improve outcomes for older adults through targeted, evidence-based prescribing.
The study will be conducted in a multidisciplinary falls clinic at Medway NHS Foundation Trust, based in Gillingham, Kent, England, UK. This secondary care setting receives referrals primarily from inpatient hospital teams and primary care practitioners. The clinic routinely assesses older adults who have experienced falls or are at high risk of falling, and conducts comprehensive geriatric assessments, including medication reviews, functional status evaluations, and frailty assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Self-administered screening tool for sarcopenia
Used to assess sarcopenia
Screening test for falls in elderly
Assessment to check for functional mobility and risk of falls.
Used to assess level of frailty.
Prevalence of exposure to one or more sarcopenia-promoting medication
Proportion of adults aged 65 years and over attending the falls clinic who are prescribed one or more sarcopenia-promoting medication. Unit of measure: % of participants.
Time frame: 6 months
Distribution of sarcopenia-promoting medication classes
Proportion of participants exposed to each medication class. Unit of measure: % of participants per medication class.
Time frame: 6 months
Number of sarcopenia-promoting medications per participant
Mean number of eligible medications prescribed per participant. Unit of measure: count.
Time frame: 6 months
Handgrip strength
Mean maximum grip strength measured with a Jamar dynamometer. Unit of Measure: Kilograms (kg).
Time frame: 6 months
Gait speed
Mean walking speed measured over 4 metres. Unit of measure: metres per second (m/s)
Time frame: 6 months
SARC-F score
SARC-F mean score. Unit of measure: points (0-10)
Time frame: 6 months
Timed Up and Go Test
Mean time taken to stand from a chair, walk 3 metres, turn, walk back and sit down. Unit of measure: Seconds (s).
Time frame: 6 months
Association between medication burden and functional performance
Comparison of grip strength, gait speed, SARC-F scores and Timed Up and Go performance across groups defined by medication burden e.g. 0-1 vs \>2 sarcopenia promoting medications. Units of measure: Differences in mean values (kg, m/s, points, seconds).
Time frame: 6 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Sep 2025 (actual). Primary completion is estimated for Feb 2027, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medway NHS Foundation Trust